These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1107 related items for PubMed ID: 15572381
1. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival. McLaughlin K, Sandhu S, Wu C, Muirhead N, Hollomby D, Jevnikar A. Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381 [Abstract] [Full Text] [Related]
2. Postlung transplant survival is equivalent regardless of cytomegalovirus match status. Russo MJ, Sternberg DI, Hong KN, Sorabella RA, Moskowitz AJ, Gelijns AC, Wilt JR, D'Ovidio F, Kawut SM, Arcasoy SM, Sonett JR. Ann Thorac Surg; 2007 Oct; 84(4):1129-34; discussion 1134-5. PubMed ID: 17888958 [Abstract] [Full Text] [Related]
3. Duration of end-stage renal disease and kidney transplant outcome. Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, Cheung AK. Nephrol Dial Transplant; 2005 Jan; 20(1):167-75. PubMed ID: 15546892 [Abstract] [Full Text] [Related]
4. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Erdbruegger U, Scheffner I, Mengel M, Schwarz A, Verhagen W, Haller H, Gwinner W. Nephrol Dial Transplant; 2012 Jan; 27(1):435-43. PubMed ID: 21712490 [Abstract] [Full Text] [Related]
5. Intermediate outcomes of dual renal allografts: the University of Washington experience. Lee RS, Miller E, Marsh CL, Kuhr CS. J Urol; 2003 Mar; 169(3):855-8. PubMed ID: 12576798 [Abstract] [Full Text] [Related]
6. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection. Chen JH, Mao YY, He Q, Wu JY, Lv R. Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078 [Abstract] [Full Text] [Related]
7. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival. Abraham KA, O'Kelly P, Spencer S, Hickey DP, Conlon PJ, Walshe JJ. Ren Fail; 2008 Dec; 30(2):141-6. PubMed ID: 18300112 [Abstract] [Full Text] [Related]
8. Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999. Smits JM, Vanhaecke J, Haverich A, de Vries E, Smith M, Rutgrink E, Ramsoebhag A, Hop A, Persijn G, Laufer G. Clin Transpl; 2003 Dec; ():89-100. PubMed ID: 15387100 [Abstract] [Full Text] [Related]
9. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients. Varga M, Rajczy K, Telkes G, Hídvégi M, Péter A, Remport A, Korbonits M, Fazakas J, Toronyi E, Sárváry E, Kóbori L, Járay J. Nephrol Dial Transplant; 2008 Aug; 23(8):2673-8. PubMed ID: 18332066 [Abstract] [Full Text] [Related]
10. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Liver Transpl; 2005 Jun; 11(6):700-4. PubMed ID: 15915496 [Abstract] [Full Text] [Related]
11. Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant? Satoskar AA, Lehman AM, Nadasdy GM, Sedmak DD, Pesavento TE, Henry ML, Pelletier RP, Ferguson RM, Nadasdy T. Clin Transplant; 2008 Jun; 22(1):61-7. PubMed ID: 18217907 [Abstract] [Full Text] [Related]
12. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Nickel P, Bold G, Presber F, Biti D, Babel N, Kreutzer S, Pratschke J, Schönemann C, Kern F, Volk HD, Reinke P. Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982 [Abstract] [Full Text] [Related]
13. Patient and graft outcomes from deceased kidney donors age 70 years and older: an analysis of the Organ Procurement Transplant Network/United Network of Organ Sharing database. Chavalitdhamrong D, Gill J, Takemoto S, Madhira BR, Cho YW, Shah T, Bunnapradist S. Transplantation; 2008 Jun 15; 85(11):1573-9. PubMed ID: 18551062 [Abstract] [Full Text] [Related]
14. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC. N Engl J Med; 1999 May 13; 340(19):1462-70. PubMed ID: 10320384 [Abstract] [Full Text] [Related]
15. Epidemiology of cytomegalovirus infection after pancreas transplantation. Parsaik AK, Bhalla T, Dong M, Rostambeigi N, Dierkhising RA, Dean P, Abraham R, Prieto M, Kremers WK, Razonable RR, Kudva YC. Transplantation; 2011 Nov 15; 92(9):1044-50. PubMed ID: 21904269 [Abstract] [Full Text] [Related]
16. Incidence and predictors of myocardial infarction after kidney transplantation. Lentine KL, Brennan DC, Schnitzler MA. J Am Soc Nephrol; 2005 Feb 15; 16(2):496-506. PubMed ID: 15615820 [Abstract] [Full Text] [Related]
17. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Dzabic M, Rahbar A, Yaiw KC, Naghibi M, Religa P, Fellström B, Larsson E, Söderberg-Nauclér C. Clin Infect Dis; 2011 Nov 15; 53(10):969-76. PubMed ID: 21960711 [Abstract] [Full Text] [Related]
18. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients. Leroy F, Sechet A, Abou Ayache R, Thierry A, Belmouaz S, Desport E, Bauwens M, Bridoux F, Touchard G. Transplant Proc; 2006 Sep 15; 38(7):2324-6. PubMed ID: 16980080 [Abstract] [Full Text] [Related]
19. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection. Christmas SE, Halliday D, Lawton N, Wang H, Abdalla I, Masters J, Hassan RL, Hart IJ, Khan N, Smith J, Hammad A, Bakran A. Transpl Immunol; 2009 Dec 15; 22(1-2):99-104. PubMed ID: 19635559 [Abstract] [Full Text] [Related]
20. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Reischig T, Jindra P, Hes O, Bouda M, Kormunda S, Treska V. Transplantation; 2009 Feb 15; 87(3):436-44. PubMed ID: 19202451 [Abstract] [Full Text] [Related] Page: [Next] [New Search]